Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

I'm fighting a fatal disease that took the life of my brother. I work in biotech and know there are medical advances that ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...

A 12-year-old boy with a severe form of muscular dystrophy has said it is "cruel" that a new drug is not being made available ...

The results suggest that prolonging ambulation may not adversely impact cardiac function in adulthood for patients with Duchenne muscular dystrophy (DMD). An analysis revealed global trends and ...

Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of ...

The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...

Medically reviewed by Smita Patel, DO Duchenne muscular dystrophy (DMD) is a rare neurological condition that causes severe muscle weakness and intellectual disability. DMD is an inherited (passed ...

Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...

About Duchenne Muscular Dystrophy (DMD) Duchenne muscular dystrophy (DMD) is a rare disease caused by mutations in the DMD gene, which encodes for the dystrophin protein. These mutations lead to ...